United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise
Rhea-AI Filing Summary
United Therapeutics Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised stock options for 9,500 shares at an exercise price of $135.42 on August 6, 2026, then sold the resulting 9,500 common shares in multiple indirect transactions at per-share prices including $512.5000 and $532.3932.
These option exercises and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026; 189,410 options remain held by the family trust, alongside direct and other indirect share holdings.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.70M approx. pre-tax spread)
Exercise and Sale
25 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($4.99M)
Approx. gross sale proceeds
$4.99M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.70M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F23 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F2 | 80 | $512.50 | $41K |
| Sale | Common Stock F1, F3, F2 | 625 | $514.9242 | $322K |
| Sale | Common Stock F1, F4, F2 | 263 | $516.2094 | $136K |
| Sale | Common Stock F1, F5, F2 | 120 | $516.7285 | $62K |
| Sale | Common Stock F1, F6, F2 | 80 | $517.825 | $41K |
| Sale | Common Stock F1, F7, F2 | 80 | $519.175 | $42K |
| Sale | Common Stock F1, F8, F2 | 633 | $520.788 | $330K |
| Sale | Common Stock F1, F9, F2 | 719 | $521.6316 | $375K |
| Sale | Common Stock F1, F10, F2 | 120 | $522.86 | $63K |
| Sale | Common Stock F1, F11, F2 | 182 | $524.2431 | $95K |
| Sale | Common Stock F1, F12, F2 | 824 | $525.4248 | $433K |
| Sale | Common Stock F1, F13, F2 | 1,357 | $526.3194 | $714K |
| Sale | Common Stock F1, F14, F2 | 1,283 | $527.2163 | $676K |
| Sale | Common Stock F1, F15, F2 | 875 | $528.2805 | $462K |
| Sale | Common Stock F1, F16, F2 | 759 | $529.3309 | $402K |
| Sale | Common Stock F1, F17, F2 | 680 | $530.4183 | $361K |
| Sale | Common Stock F1, F18, F2 | 400 | $531.417 | $213K |
| Sale | Common Stock F1, F19, F2 | 420 | $532.3932 | $224K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F20 | -- | -- | -- |
| holding | Common Stock F21 | -- | -- | -- |
| holding | Common Stock F22 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 189,410 shares (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (23)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $522.48 to $523.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $523.79 to $524.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $524.80 to $525.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $525.81 to $526.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. This transaction was executed in multiple trades at prices ranging from $526.83 to $527.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F15. This transaction was executed in multiple trades at prices ranging from $527.91 to $528.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F16. This transaction was executed in multiple trades at prices ranging from $528.95 to $529.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F17. This transaction was executed in multiple trades at prices ranging from $530.01 to $530.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F18. This transaction was executed in multiple trades at prices ranging from $531.20 to $531.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F19. This transaction was executed in multiple trades at prices ranging from $532.30 to $532.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F20. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F21. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F22. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F23. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $514.33 to $515.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $515.50 to $516.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $516.60 to $517.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $517.77 to $517.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $519.17 to $519.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $520.19 to $521.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $521.19 to $522.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 9,500 shares
Exercise price: $135.42 per share
Shares sold: 9,500 shares
+6 more
9 metrics
Options exercised
9,500 shares
Stock options exercised into common stock on August 6, 2026
Exercise price
$135.42 per share
Exercise price for stock options converted into common stock
Shares sold
9,500 shares
Common shares sold indirectly via a family trust on August 6, 2026
Lowest reported sale price
$512.5000 per share
Per-share price on one reported common stock sale transaction
Highest reported sale price
$532.3932 per share
Per-share price on one reported common stock sale transaction
Options remaining in trust
189,410 options
Stock options remaining held by a family trust after the exercise
Options in 10b5-1 plan
1,734,410 options
Total stock options covered by the Rule 10b5-1 trading plan
Direct common share holdings
40,513 shares
Common stock held directly by the reporting person after transactions
Spouse-held shares
166 shares
Common stock held indirectly by the reporting person’s spouse
Key Terms
Rule 10b5-1 trading plan, weighted average price, family trusts, investment power
4 terms
Rule 10b5-1 trading plan financial
"exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"This transaction was executed in multiple trades at prices within a range. The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries."
investment power financial
"Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did United Therapeutics (UTHR) CEO Martine Rothblatt report on August 6, 2026?
Martine Rothblatt reported exercising stock options for 9,500 United Therapeutics shares at an exercise price of $135.42 and, through a family trust, selling the resulting 9,500 common shares in multiple trades at per-share prices including $512.5000, $520.7880 and $532.3932.
Was the UTHR CEO’s stock sale made under a Rule 10b5-1 trading plan?
Yes. The disclosure states the option exercise and share sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of exercising 1,734,410 options expiring March 15, 2027 or December 31, 2026.
At what price were the United Therapeutics (UTHR) options exercised in this Form 4?
The stock options were exercised into common shares at an exercise price of $135.42 per share. These options relate to grants expiring on March 15, 2027, and are held indirectly through a family trust associated with the reporting person.
What are Martine Rothblatt’s reported United Therapeutics (UTHR) holdings after these transactions?
Reported holdings include 40,513 United Therapeutics shares held directly, 166 shares held indirectly by a spouse, and 189,410 stock options held in a family trust, along with additional indirect trust-held share positions described in the ownership footnotes.
How are the UTHR insider’s indirect holdings structured in this Form 4?
Indirect holdings are primarily in family trusts where the reporting person or spouse serves as trustee or co-trustee and shares investment power, with the reporting person and immediate family members as beneficiaries. One trust also holds the stock options that were partially exercised in this transaction.
What does the weighted average price disclosure mean in the UTHR Form 4 sales?
For several sale entries, the per-share price is a weighted average price over multiple trades within a stated range. The insider undertakes to provide full details of the number of shares and exact prices for each underlying trade upon request to regulators or security holders.